about
Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin.Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis.Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programmeSex and age discrepancy of HbA1c and fetal hemoglobin determined by HPLC in a large Chinese Han population.Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease.Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT® trial.Antioxidant strategies in the management of diabetic neuropathy.Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes.Blinded sample size recalculation in clinical trials with binary composite endpoints.Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus.Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study.
P2860
Q36989681-0FF85BEC-5AB1-4BCD-91F8-BC4A6D4ABDE5Q37257372-F7804856-964B-46B6-8CE6-A8F3AE5C27E9Q37334002-2F1D01C9-C76A-4105-97CB-0C6BA166E2FEQ38931610-C0E6C41C-E52E-42AE-B643-B63AB1347517Q39892657-BC6E59C6-0F11-4009-BADF-67CCB8943BECQ40966874-A4C730E1-6E18-43AA-886C-F52EBE467AEEQ42180667-27FA1325-6BD9-487E-ACCE-41770EE99781Q47148933-5FCA0607-66C8-45F5-84A0-559D6834DB91Q47182784-98E79D88-ADCE-4C27-87D0-3EC4A831DAFAQ47296986-484559D5-FABA-4E82-B3C8-EFE7076A30F9Q47326370-1993AF80-53EC-4A6D-9E45-10BC42E86DAFQ55284804-10BC098E-B90E-4CD3-B957-E44C861C98DC
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Composite endpoints in trials of type-2 diabetes.
@en
type
label
Composite endpoints in trials of type-2 diabetes.
@en
prefLabel
Composite endpoints in trials of type-2 diabetes.
@en
P2093
P2860
P356
P1476
Composite endpoints in trials of type-2 diabetes.
@en
P2093
P2860
P304
P356
10.1111/DOM.12226
P577
2013-11-08T00:00:00Z